Analysis of the human cancer glycome identifies a novel group of tumor-associated N-acetylglucosamine glycan antigens

Cancer Research

Volumn 69, Issue 14, 2009, Pages 5811-5819

  Satomaa, Tero ^a   Heiskanen, Annamari ^a   Leonardsson, Iréne ^c   Ångström, Jonas ^c   Olonen, Anne ^a   Blomqvist, Maria ^a   Salovuori, Noora ^a   Haglund, Caj ^b   Teneberg, Susann ^c   Natunen, Jari ^a   Carpén, Olli ^b,d   Saarinen, Juhani ^a  

^a GLYKOS FINLAND LTD   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN; GLYCOSPHINGOLIPID; N ACETYL BETA GLUCOSAMINE; N ACETYLGLUCOSAMINE; TRANSFERASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLYCOSYLATION; HUMAN; HUMAN TISSUE; LIPOGENESIS; LUNG CANCER; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; TERMINAL SEQUENCE;

ACETYLGLUCOSAMINE; GALACTOSYLTRANSFERASES; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; NEOPLASMS; POLYSACCHARIDES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 67650996838     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0289     Document Type: Article

References (49)

1. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005;5:526-42.
2. Hakomori S. Cancer-associated glycosphingolipid antigens: their structure, organization, and function. Acta Anat (Basel) 1998;161:79-90.
3. Brockhausen I. Biosynthesis and functions of O-glycans and regulation of mucin antigen expression in cancer. Biochem Soc Trans 1997;25:871-4.
4. Springer GF. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med 1997;75:594-602.
5. Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta 1999;1473:21-34.
6. Dube DH, Bertozzi CR. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat RevDrug Discov2005;4:477 -88.
7. Klinger M, Farhan H, Just H, et al. Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res 2004;64: 1087-93.
8. Partridge EA, Le RC, Di Guglielmo GM, et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 2004;306:120-4.
9. Lowe JB, Marth JD. A genetic approach to mammalian glycan function. Annu RevBiochem 2003;72:643-91.
10. Kyselova Z, Mechref Y, Kang P, et al. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem 2008;54: 1166-75.
11. Huang Y, Mechref Y, Novotny MV. Microscale non-reductive release of O-linked glycans for subsequent analysis through MALDI mass spectrometry and capillary electrophoresis. Anal Chem 2001;73:6063-9.
12. Verostek MF, Lubowski C, Trimble RB. Selective organic precipitation/extraction of released N-glycans following large-scale enzymatic deglycosylation of glycoproteins. Anal Biochem 2000;278:111-22.
13. Davies MJ, Smith KD, Carruthers RA, Chai W, Lawson AM, Hounsell EF. Use of a porous graphitised carbon column for the high-performance liquid chromatography of oligosaccharides, alditols and glycopeptides with subsequent mass spectrometry analysis. J Chromatogr 1993;646:317-26.
14. Slomianny M-C, Morelle W. In-gel release of N-linked carbohydrates from glycoproteins with analysis by matrix-assisted laser desorption/ionisation (MALDI) mass spectrometry. Sigma Origins 2004;13:4-5.
15. Saarinen J, Welgus HG, Flizar CA, Kalkkinen N, Helin J. N-glycan structures of matrix metalloproteinase-1 derived from human fibroblasts and from HT-1080 fibrosarcoma cells. Eur J Biochem 1999;259:829-40.
16. Aoki K, Perlman M, Lim JM, Cantu R, Wells L, Tiemeyer M. Dynamic developmental elaboration of N-linked glycan complexity in the Drosophila melanogaster embryo. J Biol Chem 2007;282:9127-42.
17. Natunen J, Teneberg S, Karlsson K-A, Satomaa T, Heiskanen A, inventors; Tumor specific oligosaccharides and use thereof. WO 2004/017810.
18. Hayashi T, Murray BW, Wang R, Wong CH. A chemoenzymatic synthesis of UDP-(2-deoxy-2-fluoro)-galactose and evaluation of its interaction with galactosyltransferase. Bioorg Med Chem 1997;5:497-500.
19. Ramakrishnan B, Qasba PK. Structure-based design of β1,4- galactosyltransferase I (β4Gal-T1) with equally efficient N-acetylgalactosaminyltransferase activity: point mutation broadens β4Gal-T1 donor specificity. J Biol Chem 2002;277:20833-9.
20. Dwek MV, Brooks SA, Streets AJ, Harvey DJ, Leathem AJ. Oligosaccharide release from frozen and paraffin-wax-embedded archival tissues. Anal Biochem 1996;242: 8-14.
21. Hanisch FG. O-glycosylation of the mucin type. Biol Chem 2001;382:143-9.
22. Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu RevBiochem 1985;54: 631-64.
23. Harvey DJ. Quantitative aspects of the matrix-assisted laser desorption mass spectrometry of complex oligosaccharides. Rapid Commun Mass Spectrom 1993; 7:614-9.
24. Naven TJ, Harvey DJ. Effect of structure on the signal strength of oligosaccharides in matrix-assisted laser desorption/ionization mass spectrometry on time-of-flight and magnetic sector instruments. Rapid Commun Mass Spectrom 1996;10:1361-6.
25. Papac DI, Wong A, Jones AJ. Analysis of acidic oligosaccharides and glycopeptides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Chem 1996;68:3215-23.
26. Block TM, Comunale MA, Lowman M, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A 2005; 102:779-84.
27. Chen YJ, Wing DR, Guile GR, Dwek RA, Harvey DJ, Zamze S. Neutral N-glycans in adult rat brain tissue-complete characterisation reveals fucosylated hybrid and complex structures. Eur J Biochem 1998; 251:691-703.
28. Sutton-Smith M, Morris HR, Grewal PK, et al. MS screening strategies: investigating the glycomes of knockout and myodystrophic mice and leukodystrophic human brains. Biochem Soc Symp 2002;69:105-15.
29. Kiyohara T, Terao T, Shioiri-Nakano K, Osawa T. Purification and characterization of β-N-acetylhexosaminidases and β-galactosidase from Streptococcus 6646 K. J Biochem 1976;80:9-17.
30. Anumula KR. Endo β-N-acetylglucosaminidase F cleavage specificity with peptide free oligosaccharides. J Mol Recognit 1993;6:139-45.
31. Altmann F, Schweiszer S, Weber C. Kinetic comparison of peptide: N-glycosidases F and A reveals several differences in substrate specificity. Glycoconj J 1995;12: 84-93.
32. Berger EG, Rohrer J. Galactosyltransferase - still up and running. Biochimie 2003;85:261-74.
33. Hart GW, Housley MP, Slawson C. Cycling of O-linked β-N- acetylglucosamine on nucleocytoplasmic proteins. Nature 2007;446:1017-22.
34. Spillmann D, Finne J. Specific labeling of cell surface poly-N-acetyllactosamine glycans. Methods Enzymol 1989;179:270-5.
35. Hu J, Stults CL, Holmes EH, Macher BA. Structural characterization of intermediates in the biosynthetic pathway of neolacto glycosphingolipids: differential expression in human leukaemia cells. Glycobiology 1994;4:251-7.
36. Murrell MP, Yarema KJ, Levchenko A. The systems biology of glycosylation. Chembiochem 2004;5:1334-47.
37. Raju TS, Briggs JB, Borge SM, Jones AJ. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000;10: 477-86.
38. Kyselova Z, Mechref Y, Al Bataineh MM, et al. Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res 2007;6:1822-32.
39. Brandlein S, Pohle T, Ruoff N, Wozniak E, Muller-Hermelink HK, Vollmers HP. Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res 2003;63:7995-8005.
40. Henry CJ, Buss MS, Hellstrom I, et al. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma. Clin Cancer Res 2005;11:751-5.
41. Holmberg LA, Sandmaier BM. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert RevV accines 2004;3:655-63.
42. Shriver Z, Raguram S, Sasisekharan R. Glycomics: a pathway to a class of new and improved therapeutics. Nat RevDrug Discov2004; 3:863-73.
43. Ouerfelli O, Warren JD, Wilson RM, Danishefsky SJ. Synthetic carbohydrate-based antitumor vaccines: challenges and opportunities. Expert RevV accines 2005;4: 677-85.
44. Meichenin M, Rocher J, Galanina O, et al. Tk, a new colon tumor-associated antigen resulting from altered O-glycosylation. Cancer Res 2000;60:5499-507.
45. Monzavi-Karbassi B, Luo P, Jousheghany F, et al. A mimic of tumor rejection antigen-associated carbohydrates mediates an antitumor cellular response. Cancer Res 2004;64:2162-6.
46. Callewaert N, Van VH, Van HA, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004;10:429-34.
47. Bulter T, Schumacher T, Namdjou DJ, Gutierrez GR, Clausen H, Elling L. Chemoenzymatic synthesis of biotinylated nucleotide sugars as substrates for glycosyltransferases. Chembiochem 2001;2:884-94.
48. Hoffmeister KM, Josefsson EC, Isaac NA, Clausen H, Hartwig JH, Stossel TP. Glycosylation restores survival of chilled blood platelets. Science 2003;301: 1531-4.
49. Lababede O, Meziane MA, Rice TW. TNM staging of lung cancer. Chest 1999;115:233-5.